GERMANY HAS taken a leading role in Europe’s genomics industry, and going forward the country’s contribution promises to grow. Market watchers expect some $200 million in public funds to be made available in the near future, demonstrating Germany’s commitment to staying at the forefront of innovative medical and scientific research.

All of this underscores one fundamental shift in the German mindset: People are no longer afraid of genomic and biomedical research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.